What MST could have clarified is that there are 2 MDS trials running:
a. Phase 1c/2 study in low risk MDS in Australia funded by Syntara
b. Phase 1b/2 study in high risk MDS & CMML in Germany fully funded ($2.5Mn) by the German research group with only our drug being sponsored by Syntara. 7 specialist sites willing to join this trial.
This would make the investment case look even better IMHO.
Who doesn’t like a 6X upside thesis?
SNT - Research & Valuation, page-4
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
